Trial Profile

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Hidradenitis suppurativa
Focus Registrational; Therapeutic Use
Acronyms TRuE-HS2
Sponsors Incyte Corporation

Most Recent Events

05 Jun 2025 Status changed from not yet recruiting to recruiting.
06 May 2025 Status changed from planning to not yet recruiting.
30 Jul 2024 According to an Incyte media release, company expected to initiate this trial in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com